文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

原发性骨髓纤维化:2023年诊断、风险分层和管理更新

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
PubMed 文献 · Am J Hematol · 2023-02-06

本文综述了原发性骨髓纤维化(PMF)的诊断、风险分层和管理更新,包括国际共识分类区分纤维化前与明显纤维化PMF、特定突变对生存和芦可替尼耐药的影响、GIPSS和MIPSS70+版本2.0风险分层系统,以及基于风险的观察、移植和药物治疗策略。

要点

  • 国际共识分类区分「纤维化前」与「明显纤维化」PMF,前者表现可能类似ET。
  • SRSF2、ASXL1、U2AF1-Q157突变预测较差生存,RAS/CBL突变预测芦可替尼耐药。
  • GIPSS仅基于突变和核型,MIPSSv2额外包括临床风险因素。

核心结论

  • PMF是一种干细胞来源的克隆性骨髓增殖性肿瘤,常伴JAK2、CALR或MPL突变,特征包括骨髓网状纤维/胶原纤维化、贫血、肝脾肿大等。
  • 风险 adapted 治疗:MIPSSv2低危和极低危建议观察,高危和极高危首选异基因造血干细胞移植。
  • 药物治疗目前为姑息性,靶向贫血、脾肿大和体质性症状。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • 约15%的ET或PV患者可能进展为post-ET/PV MF。
  • 1型/类似CALR突变与较好生存相关。
  • 极高危核型异常包括-7、inv(3)、i(17q)、+21、+19、12p-和11q-;有利风险异常包括正常核型或孤立+9、13q-、20q-、1q异常和Y染色体缺失。
  • MIPSSv2低危和极低危估计10年生存56%-92%;高危和极高危估计10年生存0-13%;中危估计10年生存30%。

关键数值与推荐

  • 骨髓检查联合细胞遗传学和突变研究提供整合诊断信息;JAK2、CALR或MPL突变存在是预期但非必需。
  • GIPSS完全基于突变和核型;MIPSSv2还包括临床风险因素。
  • 芦可替尼、fedratinib和pacritinib获FDA批准,分别用于羟基脲治疗失败、芦可替尼治疗失败或血小板计数<50×10^9/L的患者。
  • Momelotinib是另一种JAK2抑制剂,预计2023年获批,除影响脾和症状反应外,已显示红细胞生成益处。
  • 脾切除术考虑用于药物难治性脾肿大,累及野放疗用于非肝脾EMH和肢体骨痛。

临床怎么用

  • MIPSSv2低危和极低危疾病建议单独观察。
  • MIPSSv2高危和极高危疾病以及精心选择的中危疾病患者首选异基因造血干细胞移植。
  • JAK2抑制剂用于羟基脲或芦可替尼治疗失败或血小板计数<50×10^9/L的患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival. DIAGNOSIS: Bone marrow examination with cytogenetic and mutation studies provides integrated diagnostic information; presence of JAK2, CALR or MPL mutation is expected but not required. NEW CLASSIFICATION SYSTEM: The International Consensus Classification distinguishes "prefibrotic" from "overtly fibrotic" PMF; the former might mimic essential thrombocythemia (ET) in its presentation. Approximately 15% of patients with ET or polycythemia vera (PV) might progress into post-ET/PV MF. MUTATIONS: SRSF2, ASXL1, and U2AF1-Q157 mutations predict inferior survival in PMF; RAS/CBL mutations predict resistance to ruxolitinib therapy. Type 1/like CALR mutation is associated with superior survival. KARYOTYPE: Very high-risk abnormalities include -7, inv (3), i(17q), +21, +19, 12p- and 11q-. Favorable risk abnormalities include normal karyotype or isolated +9, 13q-, 20q-, 1q abnormalities and loss of Y chromosome. RISK STRATIFICATION: Contemporary prognostic systems include GIPSS (genetically-inspired prognostic scoring system) and MIPSS70+ version 2.0 (MIPSSv2; mutation-and karyotype-enhanced international prognostic scoring system). GIPSS is based exclusively on mutations and karyotype; MIPSSv2 includes, in addition, clinical risk factors. RISK-ADAPTED THERAPY: Observation alone is advised for MIPSSv2 "low" and "very low" risk disease (estimated 10-year survival 56%-92%); allogeneic hematopoietic stem cell transplant (AHSCT) is the preferred treatment of choice for "very high" and "high" risk disease (estimated 10-year survival 0-13%), as well as in carefully selected patients with intermediate-risk disease (estimated 10-year survival 30%). Drug therapy in MF is currently palliative and targets anemia, splenomegaly, and constitutional symptoms. JAK2 INHIBITORS: Ruxolitinib, fedratinib, and pacritinib are FDA approved and respectfully utilized in patients failing treatment with hydroxyurea, ruxolitinib, or with platelet count <50 × 10 (9)/L. Momelotinib is another JAK2 inhibitor that is poised for approval sometime in 2023 and has shown erythropoietic benefits, in addition to affecting spleen and symptom responses. OTHER TREATMENT MODALITIES: Splenectomy is considered for drug-refractory splenomegaly and involved field radiotherapy for non-hepatosplenic EMH and extremity bone pain. NEW DIRECTIONS: New agents, alone or in combination with ruxolitinib, are currently under clinical trial investigation (ClinicalTrials.gov) and preliminary results were presented at the 2022 ASH annual meeting and highlighted in the current review.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023. PMID: 36680511. doi:10.1002/ajh.26857

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。